Case Report Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/hematol.1.004
Primary CNS lymphoma (PCNSL) - Introducing to hippocampal dose-reduction whole brain radiotherapy (HDR-WBRT)
Kheng-Wei Yeoh1,*, Fang Yue Yong1, Charlene Kah Hie Wong1, Ashley Li Kuan Ong1, Thamizh Isai Swaminathan1, Kwang Ping Chan1, Muhammad Nur Hidayat Abdul Ghani1, Kevin Lee Min Chua1
- 1National Cancer Centre, 11, Hospital Drive, Singapore 169610
Corresponding Author
Kheng-Wei Yeoh, yeoh.kheng.wei@singhealth.com.sg
Received Date: May 16, 2022
Accepted Date: May 30, 2022
Yeoh KW, Yong FY, Wong CKH, Ong ALK, Swaminathan TI, Chan KP, et al. Primary CNS lymphoma (PCNSL)- Introducing hippocampal dosereduction whole brain radiotherapy (HDR-WBRT). J Clin Exp Hematol. 2022;1(1):16-19.
Copyright: © 2022 Yeoh KW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Primary central nervous system lymphoma, Neurotoxicity, WBRT, HDR-WBRT
Recommended Articles
Primary CNS lymphoma (PCNSL) - Introducing to hippocampal dose-reduction whole brain radiotherapy (HDR-WBRT)
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal Non Hodgkin Lymphoma. Combined modality treatment with high-dose methotrexate (HD-MTX) followed by whole brain radiotherapy (WBRT) has been a commonly used treatment approach.
Clinical insights and research needs in atezolizumab induced neurotoxicity
In recent years, immune checkpoint inhibitors (ICIs) have transformed the scope of cancer treatment. Atezolizumab, is a humanized monoclonal antibody that specifically targets programmed death-ligand 1 (PD-L1) to block its interaction with PD-1 and B7-1 receptors, thereby reinstating T cell response.